14/05/2026 Filing of Gazyva for additional indication of Idiopathic Nephrotic Syndrome Filing of Gazyva for additional indication of Idiopathic Nephrotic Syndrome (Ref) Chugai Pharmaceutical and Nippon Shinyaku announced that Chugai had filed a regulatory application with the Ministry of Health, Labour and Welfare (MHLW) for Gazyva® (obinutuzumab; anti-CD20) for intravenous infusion 1000 mg for an additional indication of idiopathic nephrotic syndrome (INS). The filing was ba